PNC has proven that Cyclo-Z (also known as Glucometa) is a potent stimulator of IDE synthesis. We have examined anti activities of Cyclo-Z in five different animal models: 1) Streptozotocin-induced rats (Type 1 model); 2) ob/ob mice ; 3) Goto-Kakizaki (G-K) rats 4) aging Sprague-Dawley rats (naturally induced human insulin resistance-like or mild-Type 2) and 5) high carbohydrate fed mice (over eating induced). Our colleagues at the VA Greater Los Angeles Healthcare System demonstrated that Cydo-Z treatment increased IDE synthesis in human Amyloid protein transgenic mice and stimulated degradation of Amyloid b protein and insulin. A 3 month pilot study of human subjects who used Pro-Z which contains various zinc metabolism stimulating agents showed significantly improved oral glucose tolerance test (OG1T) (measurement of insulin sensitivity) and decreased Hemoglobin A1c levels (measurement of average blood glucose concentration during the last three months). Urine glucose levels (indication of improved blood glucose control) were significantly decreased, while fasting blood glucose insignificantly decreased. In our formal FDA standard phase 1 clinical trial, acute high dose of Cydo-Z before breakfast in 12 healthy subjects significantly reduced blood glucose levels at 8 hours even after breakfast and lunch. In a pilot efficacy study, postprandial blood glucose levels, Hemoglobin A1c levels, and insulin requirement significantly decreased in 17 out of 18 subjects during 6 months. However, the physician noted that the remaining subject showed signs of improvement after more than 7 months of treatment. Some subjects stopped insulin injections completely after the 6 month treatment period.
Trustpilot
5 days ago
1 month ago
